Techno Trends
Techno Trends includes advancements and innovations in pharmaceutical products and technology from around the world. Additionally, you may keep abreast of any recent advancements in the pharmaceutical industry (product information and technological trends).
Blenrep in Combination Announces Breakthrough Therapy Designation for Relapsed/Refractory Multiple Myeloma Treatment
GSK has announced that National Medical Products Administration (NMPA) Center for Drug Evaluation has granted Breakthrough Therapy Designation (BTD) for Blenrep (belantamab mafodotin), in combination with bortezomib and dexamethasone (BorDex)...
Imfinzi Receives Priority Review and Breakthrough Therapy Status for Limited-Stage Small Cell Lung Cancer
AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), based on positive results from the ADRIATIC Phase III trial, has been accepted by the US Food and Drug Administration (FDA) and granted Priority Review....
Sanbexin Sublingual Tablets Receive FDA Breakthrough Therapy Designation
Simcere Pharmaceuticals Group Ltd. has announced that its Sanbexin Sublingual Tablets, containing edaravone and dexborneol, have been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for treating Acute Ischemic Stroke (AIS). ...
FDA Grants Breakthrough Therapy Designation to Arrowhead Pharmaceuticals for Plozasiran
Arrowhead Pharmaceuticals has revealed that the U.S. Food and Drug Administration (FDA) has awarded Breakthrough Therapy designation to their investigational drug, plozasiran....
Skyline Therapeutics Novel Gene Therapy SKG1108 Gains FDA Orphan Drug Designation for Retinitis Pigmentosa
Skyline Therapeutics has received Orphan Drug Designation (ODD) from the US Food and Drug Administration for SKG1108. This new gene therapy, delivered through a single intravitreal injection, aims to treat Retinitis Pigmentosa (RP). ...
GSK’s B7-H3 Antibody-Drug Conjugate Gains FDA Breakthrough Therapy Designation for Small-Cell Lung Cancer
The US Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to GSK5764227 an investigational antibody-drug conjugate (ADC) from GSK plc (LSE/NYSE: GSK)....
ENHERTU® Receives Breakthrough Therapy Designation for HER2 Metastatic Breast Cancer
ENHERTU® has been awarded Breakthrough Therapy Designation (BTD). This designation is for the treatment of patients with unresectable or metastatic hormone receptor-positive HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC >0 <1+) breast cancer....
Mabwell's 9MW2821 ADC Targeting Nectin-4 Receives Breakthrough Therapy Designation from NMPA
Mabwell has announced that its novel Nectin-4-targeting antibody-drug conjugate (ADC), designated as 9MW2821, has received Breakthrough Therapy Designation (BTD) from the Centre for Drug Evaluation (CDE) of China's National Medical Products...
Adaptimmune Receives FDA Accelerated Approval for TECELRA®, the First Engineered Cell Therapy for Solid Tumors
Adaptimmune Therapeutics has received approval from the U.S. FDA for TECELRA® (afamitresgene autoleucel). This treatment is intended for adults with unresectable or metastatic synovial sarcoma who have previously undergone chemotherapy and are positive for specific HLA-A types....
FDA Approves First Solid Tumor Cell Therapy, Marking a New Era in Cancer Treatment
Immunotherapies, particularly cellular immunotherapies, have transformed cancer treatment. Recent developments, such as autologous chimeric antigen receptor (CAR)-T cell therapies, have shown impressive outcomes in treating rare blood cancers....
